Preliminary data from a phase I study evaluating the novel antibody-drug conjugate M9140 demonstrated encouraging activity in heavily pretreated patients with advanced colorectal cancer. The study was presented by principal investigator Scott Kopetz, professor of gastrointestinal medical oncology and associate vice president for Translational Integration at MD Anderson, at the 2024 American Society of Clinical Oncology Annual Meeting.
Preliminary data from the first-in-human phase I trial of RO7623066—a first-in-class inhibitor of ubiquitin-specific peptidase 1—show a promising safety profile as a single agent and signs of early anti-tumor activity for patients with advanced solid tumors. The data were presented by Timothy Yap, professor of investigational cancer therapeutics and vice president and head of clinical development in MD Anderson’s Therapeutics Discovery division, at the 2024 American Society of Clinical Oncology Annual Meeting.
Purple Biotech Ltd. announced positive interim data from its randomized, controlled, open label, multicenter phase II study of CM24 in second-line metastatic pancreatic ductal adenocarcinoma presented at a late-breaking abstract poster presentation at the 2024 American Society of Clinical Oncology Annual Meeting.
Researchers at UNC Lineberger Comprehensive Cancer Center and colleagues have established the most comprehensive molecular portrait of the workings of KRAS and how its activities impact pancreatic cancer outcomes.
The American Cancer Society has published a first-of-its-kind study, “Cancer in People who Identify as Lesbian, Gay, Bisexual, Transgender, Queer or Gender-nonconforming (LGBTQ+)”.
The IQVIA Institute for Human Data Science has released its annual trends report, Global Oncology Trends 2024: Outlook to 2028.
New research out of VCU Massey Comprehensive Cancer Center—published this month in Drug Resistance Updates—revealed a previously unknown biological process through which breast tumor cells develop resistance to standard treatment. It could open the door for cancer scientists to further target this vulnerability and create more effective therapies for disease.
Up to 80% of breast cancer deaths occur in patients with tumors that express estrogen receptor-alpha, according to a study published in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research.
A multidisciplinary research team at the University of California, Irvine, has revealed that the circadian clock can be leveraged to enhance the efficacy of checkpoint inhibitor cancer therapy.
The phase III KEYNOTE-522 trial evaluating Keytruda, Merck’s anti-PD-1 therapy, met its overall survival endpoint, in combination with chemotherapy as pre-operative treatment and then continuing as a single agent after surgery for the treatment of patients with high-risk early-stage triple-negative breast cancer.
